<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="Chemical Society doi: 10.1021/acsinfecdis.0c00052 : Review Broad Spectrum Antiviral Agent" exact="Niclosamide" post="and Its Therapeutic Potential XuJiminâ€ ShiPei-Yongâ€¡Â§LiHongminâˆ¥ZhouJia*â€ Â§[], â€ â€¡Â§University"/>
 <result pre="this brief review, we summarize the broad antiviral activity of" exact="niclosamide" post="and highlight its potential clinical use in the treatment"/>
 <result pre="highlight its potential clinical use in the treatment of COVID-19." exact="niclosamide" post="broad antiviral agents coronavirus SARS-CoV MERS-CoV SARS-CoV-2 (COVID-19) flavivirus"/>
 <result pre="into four genera (alpha, beta, gamma, and delta), of which" exact="alpha" post="and beta coronaviruses are known to infect humans.2 Human"/>
 <result pre="safer and more effective drugs to be accessed by patients.8,9" exact="Niclosamide" post="is an FDA-approved anthelminthic drug that has been widely"/>
 <result pre="listed on the World Health Organizationâ€™s list of essential medicines.10,11" exact="Niclosamide" post="exerts its anticestodal effect by inhibiting oxidative phosphorylation and"/>
 <result pre="exerts its anticestodal effect by inhibiting oxidative phosphorylation and stimulating" exact="adenosine" post="triphosphatase activity in the mitochondria.12 Over the past several"/>
 <result pre="triphosphatase activity in the mitochondria.12 Over the past several years," exact="niclosamide" post="has been identified as a multifunctional drug via drug"/>
 <result pre="viral infections,19âˆ’22 and metabolic diseases.23 These broad biological activities of" exact="niclosamide" post="including relevant cell signaling pathways were briefly reviewed by"/>
 <result pre="review, we focus on summarizing the broad antiviral activities of" exact="niclosamide" post="(Figure 1) and highlighting its therapeutic potential in combating"/>
 <result pre="and highlighting its therapeutic potential in combating COVID-19. Figure 1" exact="Niclosamide" post="has great potential in being repurposed to treat a"/>
 <result pre="vivo toxicity profile as an FDA-approved drug in clinical use." exact="Niclosamide" post="and Viral Infections Niclosamide and Coronavirus Coronaviruses are a"/>
 <result pre="an FDA-approved drug in clinical use. Niclosamide and Viral Infections" exact="Niclosamide" post="and Coronavirus Coronaviruses are a group of enveloped and"/>
 <result pre="need for new drug discovery. Wu et al. found that" exact="niclosamide" post="was able to inhibit SARS-CoV replication and totally abolished"/>
 <result pre="of 1.56 Î¼M after screening a small marketed drug library.27" exact="Niclosamide" post="suppressed the cytopathic effect (CPE) of SARS-CoV at a"/>
 <result pre="was discovered as potent inhibitors against SARS-CoV 3CL protease. Interestingly," exact="niclosamide" post="showed no obvious inhibitory activity against SARS-CoV 3CL protease"/>
 <result pre="the BENC1 level, enhances autophagy, and efficiently reduces MERS-CoV replication.33" exact="Niclosamide" post="was reported to inhibit MERS-CoV replication by up to"/>
 <result pre="and affected the autophagic flux in the MERS-CoV-infected cells.33 Since" exact="niclosamide" post="is a multifunctional drug, we cannot exclude the possibility"/>
 <result pre="its anti-MERS activity by regulating other targets besides SKP2 inhibition." exact="Niclosamide" post="and Flavivirus Flavivirus, a genus of viruses in the"/>
 <result pre="used caspase-3 activity as the primary screening assay and discovered" exact="niclosamide" post="as a potent inhibitor of ZIKV infection, displaying an"/>
 <result pre="the intracellular ZIKV RNA level.22 The time-of-addition studies indicated that" exact="niclosamide" post="inhibits ZIKV infection at a postentry stage, probably in"/>
 <result pre="a viral RNA replication step. Our research team also identified" exact="niclosamide" post="as a potent anti-ZIKV inhibitor through an independent quantitative"/>
 <result pre="an independent quantitative high-throughput screening (qHTS) campaign and found that" exact="niclosamide" post="directly inhibits flavivirus NS2B-NS3 interactions.14 Protease complex NS2B-NS3 is"/>
 <result pre="essential for flaviviral polyprotein processing.39âˆ’41 Our team also found that" exact="niclosamide" post="is a broad-spectrum inhibitor against other flaviviruses including DENV-2,"/>
 <result pre="HTS assay to screen 1280 pharmacologically active compounds and identified" exact="niclosamide" post="as a potent JEV inhibitor with micromolar potency.42 The"/>
 <result pre="JEV inhibitor with micromolar potency.42 The time-of-addition studies showed that" exact="niclosamide" post="inhibits JEV at the stage of replication. Niclosamide and"/>
 <result pre="showed that niclosamide inhibits JEV at the stage of replication." exact="Niclosamide" post="and Hepatitis C Virus Hepatitis C virus (HCV) is"/>
 <result pre="vaccine against hepatitis C, although clinically approved therapeutics are available." exact="Niclosamide" post="was reported to show very promising activity against HCV"/>
 <result pre="antiviral treatment, which may make a host-targeted approach less attractive." exact="Niclosamide" post="and Ebola Virus Ebola virus (EBOV) is an enveloped"/>
 <result pre="in past outbreaks. Through a systematic screen of FDA-approved drugs," exact="niclosamide" post="was identified as one of the most potent EBOV"/>
 <result pre="vivo efficacy has not yet been evaluated in animal models.48" exact="Niclosamide" post="and Human Rhinovirus Human rhinoviruses (HRVs) are nonenveloped, positive-sense"/>
 <result pre="chronic pulmonary disease, and severe bronchiolitis in infants and children.49" exact="Niclosamide" post="is a weak lipophilic acid and was reported to"/>
 <result pre="acidification of the endolysosomal compartments, acting as a proton carrier.50" exact="Niclosamide" post="and Chikungunya Virus Chikungunya virus (CHIKV) is a positive-sense"/>
 <result pre="Currently, there is no effective antiviral therapy approved for Chikungunya." exact="Niclosamide" post="was discovered as a potent anti-CHIKV inhibitor with a"/>
 <result pre="fusion but also inhibits the cell-to-cell transmission of CHIKV infection.51" exact="Niclosamide" post="and Human Adenovirus Human adenoviruses (HAdVs) are nonenveloped double-stranded"/>
 <result pre="available to treat these infections. Three salicylanilide anthelmintic drugs including" exact="niclosamide" post="were screened out as potent anti-HAdV inhibitors. Niclosamide showed"/>
 <result pre="drugs including niclosamide were screened out as potent anti-HAdV inhibitors." exact="Niclosamide" post="showed very promising anti-HAdV activity with an EC50 value"/>
 <result pre="Î¼M in the plaque assay. Subsequent mechanistic studies indicated that" exact="niclosamide" post="inhibits the transport of the HAdV particle from the"/>
 <result pre="the HAdV particle from the endosome to the nuclear envelop.52" exact="Niclosamide" post="and Epsteinâ€&quot;Barr Virus Epsteinâ€&quot;Barr virus (EBV), also known as"/>
 <result pre="Hodgkinâ€™s lymphoma, and nasopharyngeal carcinoma.53 Huang et al. demonstrated that" exact="niclosamide" post="inhibits EBV lytic replication in lymphoma cells and epithelial"/>
 <result pre="to treat acute EBV-associated infectious diseases.54 Conclusions and Future Directions" exact="Niclosamide" post="has traditionally been used to treat tapeworm infections for"/>
 <result pre="single oral doses of 0.5, 1, and 2 g of" exact="niclosamide" post="are recommended for children under 2 years, children between"/>
 <result pre="were eliminated by 5â€&quot;7 daily doses of 2 g of" exact="niclosamide" post="each, while the treatment of Hymenolepis nana infection requires"/>
 <result pre="nana infection requires one or several 5â€&quot;7 day courses of" exact="niclosamide" post="treatment. One 7 day course regimen for adults is"/>
 <result pre="7 day course regimen for adults is 2 g of" exact="niclosamide" post="on day 1 followed by 1 g daily for"/>
 <result pre="of 2000 mg of niclosamide, the maximum serum concentration of" exact="niclosamide" post="was equivalent to 0.25â€&quot;6.0 Î¼g/mL (0.76â€&quot;18.3 Î¼M). The wide"/>
 <result pre="wide concentration range was caused by the intraindividual absorption differences." exact="Niclosamide" post="is only partially absorbed from the intestinal tract, and"/>
 <result pre="in human.10 Through a series of drug repurposing screening campaigns," exact="niclosamide" post="was found to be effective against a variety of"/>
 <result pre="infections. Currently, there are four ongoing human clinical trials of" exact="niclosamide" post="in ulcerative colitis, prostate carcinoma, and colorectal cancer in"/>
 <result pre="colorectal cancer in the ClinicalTrails.gov clinical trials registry.56 Of note," exact="niclosamide" post="has several weaknesses such as unneglectable cytotoxicity and limited"/>
 <result pre="group has made substantial efforts in medicinal chemistry based on" exact="niclosamide" post="as a lead compound and discovered a series of"/>
 <result pre="orally bioavailable anticancer agents with improved aqueous solubility16 and diversified" exact="salicylamide" post="derivatives as potent anti-HAdV inhibitors with increased potency (submicromolar"/>
 <result pre="in the HAdV life cycle.58 The ester derivative prodrug of" exact="niclosamide" post="was also reported to increase its systemic drug exposure"/>
 <result pre="useful strategy for improving the pharmacological and pharmacokinetic properties of" exact="niclosamide" post="and maximizing its therapeutic potential for clinical applications.60âˆ’62 The"/>
 <result pre="a prodrug of tizoxanide, which shares considerable structural similarity with" exact="niclosamide" post="as a salicylamide derivative.47 Notably, niclosamide displays promising inhibitory"/>
 <result pre="tizoxanide, which shares considerable structural similarity with niclosamide as a" exact="salicylamide" post="derivative.47 Notably, niclosamide displays promising inhibitory activity against SARS-CoV"/>
 <result pre="considerable structural similarity with niclosamide as a salicylamide derivative.47 Notably," exact="niclosamide" post="displays promising inhibitory activity against SARS-CoV replication with an"/>
 <result pre="activity is validated in animal models or human clinical trials," exact="niclosamide" post="and its optimized analogues may be developed as effective"/>
 <result pre="ChuL.; ZhangY.; TerryK.; LiuH.; ShenQ.; ZhouJ. (2013) Discovery of O-alkylamino-tethered" exact="niclosamide" post="derivatives as potent and orally bioavailable anticancer agents. ACS"/>
 <result pre="ZhangY.; ChelluriR.; BoufraqechM.; NilubolN.; PatelD.; ShenM.; KebebewE. (2016) Identification of" exact="niclosamide" post="as a novel anticancer agent for adrenocortical carcinoma. Clin."/>
 <result pre="ClayT. M.; ChenW.; MorseM. A.; LyerlyH. K. (2011) Antihelminth compound" exact="niclosamide" post="downregulates Wnt signaling and elicits antitumor responses in tumors"/>
 <result pre="XuJ.; PachÃ³n-IbÃ¡Ã±ezM. E.; Cebrero-CangueiroT.; ChenH.; SÃ¡nchez-CÃ©spedesJ.; ZhouJ. (2019) Discovery of" exact="niclosamide" post="and its O-alkylamino-tethered derivatives as potent antibacterial agents against"/>
 <result pre="D.; EndsleyJ. J.; ZhouJ.; EndsleyM. A. (2019) Dual activity of" exact="niclosamide" post="to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis"/>
 <result pre="Med.22, 1101â€&quot;1107. 10.1038/nm.4184.27571349 TaoH.; ZhangY.; ZengX.; ShulmanG. I.; JinS. (2014)" exact="Niclosamide" post="ethanolamineâ€&quot;induced mild mitochondrial uncoupling improves diabetic symptoms in mice."/>
 <result pre="NS3 proteinase domain and NS2B are required for cleavages at" exact="dibasic" post="sites. J. Virol.65, 6042â€&quot;6050. 10.1128/JVI.65.11.6042-6050.1991.1833562 FalgoutB.; PethelM.; ZhangY. M.;"/>
 <result pre="135â€&quot;162. 10.1128/CMR.00077-12.23297263 JurgeitA.; McDowellR.; MoeseS.; MeldrumE.; SchwendenerR.; GreberU. F. (2012)" exact="Niclosamide" post="is a proton carrier and targets acidic endosomes with"/>
 <result pre="ChinY.-F.; WuT.-Y.; LinL.-I.; LaiZ.-Z.; KuoS.-C.; HoY.-J. (2016) Antiviral activities of" exact="niclosamide" post="and nitazoxanide against chikungunya virus entry and transmission. Antiviral"/>
 <result pre="Mech. Dis.1, 375â€&quot;404. 10.1146/annurev.pathol.1.110304.100209. HuangL.; YangM.; YuanY.; LiX.; KuangE. (2017)" exact="Niclosamide" post="inhibits lytic replication of Epstein-Barr virus by disrupting mTOR"/>
 <result pre="disrupting mTOR activation. Antiviral Res.138, 68â€&quot;78. 10.1016/j.antiviral.2016.12.002.27939840 JonesW. E. (1979)" exact="Niclosamide" post="as a treatment for Hymenolepis diminuta and Dipylidium caninum"/>
 <result pre="ChangY.-W.; YehT.-K.; LinK.-T.; ChenW.-C.; YaoH.-T. (2006) Pharmacokinetics of anti-SARS-CoV agent" exact="niclosamide" post="and its analogs in rats. J. Food Drug Anal.14,"/>
 <result pre="ChenH.; PachÃ³nJ.; ZhouJ.; Sanchez-CespedesJ. (2020) Structure-activity relationship studies on diversified" exact="salicylamide" post="derivatives as potent inhibitors of human adenovirus infection. J."/>
 <result pre="K.; ChenW. (2015) Structureâ€&quot;activity studies of Wnt/Î²-catenin inhibition in the" exact="Niclosamide" post="chemotype: Identification of derivatives with improved drug exposure. Bioorg."/>
 <result pre="BarbosaE. J.; LÃ¶benbergR.; de AraujoG. L. B.; Bou-ChacraN. A. (2019)" exact="Niclosamide" post="repositioning for treating cancer: Challenges and nano-based drug delivery"/>
 <result pre="BiancaR.; SorrentinoR.; MiroA.; QuagliaF.; ImperiF.; LeoniL.; UngaroF. (2015) Toward repositioning" exact="niclosamide" post="for antivirulence therapy of Pseudomonas aeruginosa lung infections: Development"/>
 <result pre="YangX.; LiuJ.; XuM.; ShiZ.; HuZ.; ZhongW.; XiaoG. (2020) Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
</results>
